Loading
Histone Deacetylase Inhibitors Research · Journal article
Cancer Gene Therapy · August 13, 2026
Raises a question worth testing. It does not answer one.
This is an exploratory in vitro mechanistic study proposing that histone deacetylase inhibitors induce quiescence in ovarian cancer cells by disrupting NuRD complex components and RHO/RAC signalling, and that this quiescent state sensitizes cells to proteostasis inhibitors. The work raises a hypothesis for future preclinical and clinical investigation but provides no efficacy or safety data suitable for clinical translation.
In vitro mechanistic cell culture study with gene knockdown and pharmacologic screening. Ovarian cancer cell lines, cultured in vitro. Intervention: CHD4 or MBD3 knockdown, histone deacetylase inhibitors (HDACi), RAC inhibitors (RACi), proteasome inhibitors, autophagy inhibitors, and combination therapies. Compared with: Untreated or vehicle control (not explicitly stated).
CHD4 and MBD3 components of the NuRD complex are downregulated in quiescent ovarian cancer cells Histone deacetylase inhibitors induce quiescence in ovarian cancer cells, confirmed by RNA-Seq and ATAC-seq HDACi-treated cells show downregulation of RHO/RAC pathways and nuclear-to-cytoplasmic shifting of MRTFA transcription factor
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This study does not yet support clinical use of HDACi–proteostasis inhibitor combinations. The findings are preclinical and require validation in animal models and subsequent clinical trials before informing treatment decisions.
Mechanistic study identifying pathways and proposing a combination therapy strategy in cell culture without in vivo validation or clinical outcome data.
As stated by the source record.
Quoted from the source exactly as published.
This study does not yet support clinical use of HDACi–proteostasis inhibitor combinations. The findings are preclinical and require validation in animal models and subsequent clinical trials before informing treatment decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Chemotherapy remains the primary treatment for ovarian cancer (OvCa), and chemoresistance drives patient mortality. Cellular quiescence, reversible exit from the cell cycle, increases chemotherapy resistance as chemotherapies primarily target rapidly proliferating cells. Here, we report that CHD4 and MBD3, components of the nucleosome remodeling and deacetylase (NuRD) complex, are downregulated in quiescent OvCa cells (qOvCa). We find that either CHD4 or MBD3 knockdown or histone deacetylase inhibitors (HDACi), induce quiescence in OvCa cells. RNA-Seq and ATAC-seq analysis of HDACi-treated cells confirmed expression changes consistent with induction of quiescence. Additionally, HDACi-treated cells revealed downregulation of the RHO/RAC pathways. Suggesting downregulation of the RAC pathway could play a role in HDACi-mediated quiescence, RAC inhibitors (RACi) similarly induced quiescence. Both HDACi and RACi resulted in nuclear-to-cytoplasmic shifting of the pro-proliferative transcription factor MRTFA. which has been linked to quiescence. Further analysis of HDACi qOvCa indicated multiple alterations in proteostasis, including increased proteasome activity and autophagy. We find qOvCa cells are dependent on these pathways for survival, such that there is profound synergistic OvCa cell death with HDACi and proteasome- or autophagy-inhibitor combination therapy. Combined, this work supports HDACi as pharmacologic means to induce a quiescent state in OvCa cells and sensitize them to proteostasis-targeting drugs.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.